News &
Announcements

The US Food and Drug Administration (FDA) has approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.

FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A | FDA